Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LioCyx in Recurrent HBV-Related HCC Post Liver Transplant
NCT03634683Phase 2Withdrawn
- Sponsor
- Lion TCR
- Start
- Aug 2018
- Primary completion
- Aug 2022
- Modality
- Gene Editing, Bone Marrow HSCs, Gene Silencing
- Countries
- 2
01
Overview
A Phase 2 trial of liocyx-m in hepatocellular carcinoma (HCC), sponsored by Lion TCR. Planned start Aug 2018; status: withdrawn.
02
Drugs
liocyx-m
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03634683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634683.